OLOGY URS

Home
OLOGY URS

At Ology, we focus on tailored services that best meet the needs of your company. Please send us a message or call us for an appointment.

Rather you are getting started or near the end of your clinical trial and you need additional resources, we are here to help push your team to the finish line.

14/05/2023

Happy Mother's Day to each of you from Ology! We ouldn't do this life without youi! We would like to extend a special shout out to one of the hardest working mother's we know. Sarah we love and appreciate you!

11/05/2023

The benefits of (cladribine) were sustained for up to 15 years after its last treatment course in people with relapsing multiple sclerosis (MS), according to real-world data from the CLASSIC-MS study. More than half of those who received the oral therapy in the clinical trials that supported its approval no longer needed further disease-modifying therapies (DMTs) and twice as many continued relapse-free over a median of 10.9 years compared with those never given it.

Read full article:
https://multiplesclerosisnewstoday.com/news-posts/2023/04/11/mavenclad-benefits-ms-sustained-up-15-years-after-last-treatment/

09/05/2023

H. Lee Moffitt Cancer Center and Research Institute is enrolling 18 participants, 18 Years and older, for A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV). The purpose of this study is to learn about the effects of the study treatment, Dendritic Cell Vaccine (DCV), to find the highest dose of the study treatment that can be given safely to Breast Cancer patients with Leptomeningeal Disease.
For more details about enrollment visit: https://clinicaltrials.gov/ct2/show/NCT05809752?recrs=a&draw=4&rank=26

05/05/2023

Happy Cinco de Mayo from Ology!

Read one persons Cinco de Mayo (Clinic) experience: https://braintumor.org/news/cinco-de-mayo-clinic/

03/05/2023

Word Wednesday!

ALL-CAUSE MORTALITY: A measure of all deaths, due to any cause, that occur during a clinical study.

01/05/2023

The Janssen Pharmaceutical Companies of Johnson & Johnson has announced new long-term data from its CHRYSALIS study.

Repost from:
https://www.linkedin.com/posts/pharmemed_janssens-rybrevant-yields-positive-data-activity-7047680225219928064-sReY?utm_source=share&utm_medium=member_desktop

27/04/2023

Researchers are conducting what they call a first of its kind clinical trial to study how Hispanic and Black patients respond to a common medication for multiple sclerosis.
About 30% of people with MS in the United States are Black and Latino Americans, but they make up less than 5% of MS clinical trials participants, according to neurologist Mitzi Joi Williams, who is leading the new research.
What they're saying: "We hope to identify more insights into the unique nature of MS in these underrepresented populations so we can ultimately ensure we’re providing individuals with the best possible personalized care," Williams told Axios Latino.

Read more about this trial at: https://www.axios.com/2023/04/11/multiple-sclerosis-latino-black-american-health

26/04/2023

WORD WEDNESDAY!

RANDOMIZED ALLOCATION: A type of allocation strategy in which participants are assigned to the arms of a clinical trial by chance.

25/04/2023

Trailing and , reports phase 3 ovarian cancer success for Lynparza rival!

Read full article at: https://www.fiercebiotech.com/biotech/trailing-astrazeneca-and-merck-junshi-reports-phase-3-ovarian-cancer-success-lynparza-rival

19/04/2023

Word Wednesday!

ACCPETS HEALTHY VOLUNTEERS: A type of eligibility criteria that indicates whether people who do not have the condition/disease being studied can participate in the clinical study.

17/04/2023

Repost from

Researchers at are looking to enroll people with diabetes for a study on the role of Vitamin C in the red blood cells of those with . Call now 866-444-1134 or email ccopr@nih.gov for study #14-DK-0060 https://go.usa.gov/xyTaY

https://twitter.com/NIHClinicalCntr/status/1646166284030050306?s=20

14/04/2023

Merck & Co – known as MSD outside the US and Canada – and Proxygen have entered into a multi-year research collaboration and licensing agreement to jointly identify molecular glue degraders against multiple undisclosed therapeutic targets.
Under the terms of the agreement, the Austrian biotech will receive an upfront payment from Merck and will be eligible for future payments of up to $2.55bn plus royalties. The deals are based on Proxygen’s platform technology and capabilities in identifying novel molecular glue degraders, which are designed to reprogramme the cell’s natural recycling machinery to selectively eliminate disease-causing proteins.
Click on one of the links to read more.

https://www.linkedin.com/posts/pharmemed_merck-and-proxygen-partner-in-deal-worth-activity-7049722308243922944-xXoq?utm_source=share&utm_medium=member_desktop

https://www.pmlive.com/pharma_news/merck_and_proxygen_partner_in_deal_worth_up_to_$2.5bn_1490455

13/04/2023

is NOW Recruiting for a basic investigational research study conducted with hearing impaired adults and children who use cochlear implant or auditory brainstem implant (ABI) devices. The study will evaluate different aspects of hearing and auditory processing in the users of implantable auditory devices. For more details click on the link below.
https://clinicaltrials.gov/ct2/show/NCT05810220?recrs=a&draw=3&rank=15

12/04/2023

WORD WEDNESDAY!

SECONDARY OUTCOME MEASURE: In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.

05/04/2023

WORD WEDNESDAY!

TITLE: The official title of a protocol used to identify a clinical study or a short title written in language intended for the lay public.

29/03/2023

WORD WEDNESDAY!

U.S. Food and Drug Administration (FDA): An agency within the U.S. Department of Health and Human Services. The FDA is responsible for protecting the public health by making sure that human and veterinary drugs, vaccines and other biological products, medical devices, the Nation's food supply, cosmetics, dietary supplements, and products that give off radiation are safe, effective, and secure.

27/03/2023

Novo Nordisk and Dewpoint Therapeutics have entered into a research and development partnership aimed at identifying drug candidates to treat insulin resistance and diabetic complications.
A key driver of type 2 diabetes and metabolic syndrome, insulin resistance occurs when the body has an impaired response to insulin, resulting in elevated levels of glucose in the blood.
The condition is rising in prevalence globally, affecting 15.5% to 46.5% of the world’s population.
The collaboration will see the partners use Dewpoint’s discovery and AI technology platform to identify modulators of biomolecular condensates – membraneless organelles comprising proteins and RNA – that may be involved in insulin resistance and insulin sensitivity.
The dysregulation of these condensates has been observed in many diseases, including diabetes, which is why Dewpoint believes that using its platform to develop condensate-modifying drugs could provide new therapeutic options for complex diseases and historically ‘undruggable’ targets.
Ameet Nathwani, chief executive officer of Dewpoint, said: “We believe that by discovering and hopefully reversing the dysregulation of biomolecular condensates that leads to insulin resistance, we have the potential to profoundly impact the development and clinical course of diabetes, one of the most profound global health challenges affecting society today.”
As part of the collaboration, Novo Nordisk can also choose to discover non-small molecule drugs to treat the identified condensates using its internal capabilities and gains rights to further develop and commercialize such potential drugs.

Read more: https://lnkd.in/exNYQFhZ

(repost from https://www.linkedin.com/company/pharmemed/posts/?feedView=all)

23/03/2023

"It is no secret that there is a lack of diversity in clinical research. With fewer than five percent of all adults diagnosed with cancer participating in trials, the adverse effects of this disparity are magnified when it comes to the treatment and care of minority patients. The disparities in clinical trials significantly impact the efficacy of treatment for underrepresented groups. This impact will only increase as the trend of personalized medicine continues and treatments like immunotherapy are explicitly tailored to one’s genotype. Without sufficient data regarding a patient group, doctors have limited ability to predict how they may respond to treatment. For example, a study published in 2017 found that some African Americans have lung tumors with a different gene expression than those found in white patients. This could impact the efficacy of specific therapies."

To read the full article visit: https://lcfamerica.org/lung-cancer-info/lack-of-diversity-in-clinical-trials/

Address

Opening Hours

Monday	08:00 - 17:00
Tuesday	08:00 - 17:00
Wednesday	08:00 - 17:00
Thursday	08:00 - 17:00
Friday	08:00 - 17:00

Telephone

+19494316624

Website

https://ologyurs.com/

Alerts

Be the first to know and let us send you an email when OLOGY URS posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to OLOGY URS:

Shortcuts

Address
Telephone
Opening Hours
Alerts
Contact The Practice
Claim ownership or report listing
Want your practice to be the top-listed Clinic?

Country:

City: